Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Apr;23(4):319-327.
doi: 10.7499/j.issn.1008-8830.2101174.

[Pediatric expert consensus on the application of intravenous immunoglobulin in children with hematological/neoplastic diseases]

[Article in Chinese]
Pediatric Branch of Guangdong Medical Association; Editorial Department of Chinese Journal of Contemporary Pediatrics

[Pediatric expert consensus on the application of intravenous immunoglobulin in children with hematological/neoplastic diseases]

[Article in Chinese]
Pediatric Branch of Guangdong Medical Association et al. Zhongguo Dang Dai Er Ke Za Zhi. 2021 Apr.

Abstract
in English, Chinese

Intravenous immunoglobulin (IVIG) has been widely used in chemotherapy for hematological malignancies, targeted therapy, and hematopoietic stem cell transplantation; however, there are still no available guidelines or consensus statements on the application of IVIG in pediatric hematological/neoplastic diseases at present in China and overseas. This consensus is developed based on the research advances in the application of IVIG in pediatric hematological/neoplastic diseases across the world and provides detailed recommendations for the clinical application of IVIG in pediatric hematological/neoplastic diseases and the prevention and treatment of related adverse reactions.

静脉注射用免疫球蛋白（IVIG）在恶性血液肿瘤化疗、靶向治疗及造血干细胞移植中的应用越来越普遍，但国内外尚无儿童血液/肿瘤性疾病中IVIG应用的临床指南或共识。该共识基于儿童血液/肿瘤性疾病中IVIG应用的国内外研究进展而制定，对IVIG在儿童血液/肿瘤性疾病中的临床应用策略及其不良反应的防治提出具体建议。

PubMed Disclaimer

Conflict of interest statement

利益冲突声明：所有作者均声明不存在利益冲突。

References

    1. Imbach P, Barandun S, Baumgartner C, et al. High-dose intravenous gammaglobulin therapy of refractory, in particular idiopathic thrombocytopenia in childhood. Helv Paediatr Acta. 1981;36(1):81–86. - PubMed
    1. CSCO肿瘤相关性贫血专家委员会 EPO治疗肿瘤相关性贫血中国专家共识(2010-2011版) 临床肿瘤学杂志. 2010;15(10):925–936. doi: 10.3969/j.issn.1009-0460.2010.10.016. - DOI
    1. Prins C, Gelfand EW, French LE. Intravenous immunoglobulin: properties, mode of action and practical use in dermatology. Acta Derm Venereol. 2007;87(3):206–218. - PubMed
    1. Imbach P, Barandun S, d'Apuzzo V, et al. High-dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood. Lancet. 1981;1(8232):1228–1231. - PubMed
    1. Provan D, Arnold DM, Bussel JB, et al. Updated international consensus report on the investigation and management of primary immune thrombocytopenia. Blood Adv. 2019;3(22):3780–3817. doi: 10.1182/bloodadvances.2019000812. - DOI - PMC - PubMed

Publication types

Substances

LinkOut - more resources